Form 4: Contineum Therapeutics CEO Sells Shares Under 10b5-1 Plan

Contineum Therapeutics CEO and President Carmine N. Stengone executed planned sales of Class A Common Stock totaling 7,100 shares in late February 2026.

Summary

• Carmine N. Stengone, CEO and President of Contineum Therapeutics, Inc. (CTNM), engaged in transactions involving the company's Class A Common Stock.
• On February 24, 2026, Stengone acquired 4,400 shares by exercising stock options at $1.26 per share and simultaneously sold 4,400 shares at a weighted average price of $16.0195.
• On February 25, 2026, Stengone acquired an additional 2,700 shares by exercising stock options at $1.26 per share and simultaneously sold 2,700 shares at a weighted average price of $16.0155.
• These transactions were executed under a pre-arranged 10b5-1 trading plan adopted on September 23, 2025.
• Following these transactions, Stengone directly beneficially owns 14,954 shares of Class A Common Stock and 120,917 stock options.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event. While an insider sale can be perceived negatively, the pre-arranged 10b5-1 plan mitigates concerns about its timing or implications for the company's immediate prospects.

Positives

• The exercise of stock options indicates that the options were in-the-money, reflecting a significant difference between the exercise price ($1.26) and the sale price (around $16.00).
• The transactions were conducted under a pre-arranged 10b5-1 trading plan, which suggests a systematic approach to managing personal holdings rather than a reaction to immediate company news.

Negatives

• The sale of 7,100 shares by a key executive (CEO and President) reduces their direct equity stake in the company.

Industry Context

StockSavvy.ai notes that insider transactions, particularly sales by top executives, are routinely disclosed via Form 4 filings. While a sale can sometimes be interpreted negatively, the execution under a 10b5-1 plan indicates a pre-scheduled transaction, often for personal financial planning, rather than a reaction to new, undisclosed information about the company's performance or industry trends.

Stakeholder Impact

• Shareholders may observe a slight reduction in direct insider ownership, though the pre-planned nature of the sale lessens concerns about its implications for company fundamentals.

Key Dates

Recommendation

The transactions represent routine insider activity under a pre-established 10b5-1 plan, which typically does not signal a change in the company's fundamental outlook. While the CEO is selling shares, the pre-planned nature suggests personal financial management rather than a bearish view on the company. Therefore, a 'hold' recommendation is appropriate as this filing alone does not provide new information to alter an investment thesis.

Keywords

Contineum Therapeutics, CTNM, Carmine N. Stengone, Insider Trading, Form 4, Stock Option Exercise, Share Sale, 10b5-1 Plan, CEO, Director